Clinical Efficacy of Modified Linggui Zhugan Tang in Patients with Obstructive Sleep Apnea-Hypopnea Syndrome of Spleen Deficiency and Dampness Obstruction with Blood Stasis Type and Its Effect on MIF， miR-223， and IL-18
10.13422/j.cnki.syfjx.20251024
- VernacularTitle:加味苓桂术甘汤对阻塞性睡眠呼吸暂停低通气综合征脾虚湿阻夹瘀型患者临床疗效及对MIF、miR-223及IL-18的影响
- Author:
Jun ZHANG
1
;
Mengmei WEI
2
;
Bo LI
2
;
Yi YANG
2
;
Changhui LINGHU
2
;
Mingchang ZHANG
3
;
Zhengxing GE
2
Author Information
1. Guizhou University of Traditional Chinese Medicine（TCM）， Guiyang 550025，China
2. The Second Affiliated Hospital of Guizhou University of TCM， Guiyang 550003，China
3. Qiannan Prefecture Hospital of TCM， Qiannan 558000，China
- Publication Type:Journal Article
- Keywords:
modified Linggui Zhugan Tang;
obstructive sleep apnea-hypopnea syndrome （OSAHS）;
spleen deficiency and dampness obstruction with blood stasis;
inflammatory factors;
clinical efficacy
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2026;32(9):171-179
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the intervention effects of modified Linggui Zhugan Tang （LGZGT） on patients with obstructive sleep apnea-hypopnea syndrome （OSAHS） of the spleen deficiency and dampness obstruction with blood stasis type， reveal its possible mechanisms， and provide a theoretical basis for the clinical treatment of OSAHS with traditional Chinese medicine （TCM）. MethodsEighty OSAHS patients with spleen deficiency and dampness obstruction with blood stasis were randomly assigned to a control group and an observation group （1∶1） using a random number table， with 40 patients in each group. The control group received standard basic treatment combined with oral Doxofylline tablets， while the observation group received standard basic treatment combined with modified LGZGT. Serum levels of macrophage migration inhibitory factor （MIF）， microRNA-223 （miR-223）， and interleukin-18 （IL-18） were measured by enzyme-linked immunosorbent assay （ELISA）， and the mRNA expression levels of MIF， miR-223， and IL-18 were measured by real-time quantitative polymerase chain reaction （Real-time PCR）. After two months of treatment， the total clinical efficacy， apnea-hypopnea index （AHI）， lowest nocturnal oxygen saturation （LSpO2）， body mass index （BMI）， TCM syndrome scores， and expression levels of MIF， miR-223， and IL-18 before and after treatment were compared between the two groups. Correlations between MIF， miR-223， IL-18 and AHI and LSpO2 were also analyzed. ResultsCompared with the control group， the observation group showed a significantly higher total clinical effective rate （P<0.01， Z=-3.49）. Within the control group， no significant changes were observed in AHI， LSpO2， BMI， TCM syndrome scores， or MIF， miR-223， IL-18 levels and their mRNAs after treatment. In the observation group， AHI， BMI， TCM syndrome scores， and MIF and IL-18 levels and their mRNAs decreased significantly， while LSpO2 increased significantly （P<0.01）. After treatment， compared with the control group， the observation group exhibited significantly lower AHI， BMI， TCM syndrome scores， and MIF and IL-18 levels and their mRNAs， and significantly higher LSpO2 （P<0.01）. Correlation analysis showed that MIF and IL-18 were positively correlated with AHI （P<0.01） and negatively correlated with LSpO2 （P<0.01）， whereas miR-223 was negatively correlated with AHI （P<0.01） and positively correlated with LSpO2 （P<0.01）. ConclusionModified LGZGT may improve OSAHS of the spleen deficiency and dampness obstruction with blood stasis type by reducing airway inflammatory factors， alleviating airway inflammation， relieving airway edema and stenosis， and improving airway obstruction.
